Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, explains the rationale and design of an ongoing Phase III study comparing consolidation with autologous transplantation followed by rituximab vs rituximab maintenance alone in patients with mantle cell lymphoma (MCL) in MRD-negative first complete remission (NCT03267433). This study aims to determine whether all patients with MCL benefit from stem cell transplantation (SCT) or if some patients could derive more benefit from other therapies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.